iShares Healthcare Innovation UCITS ETF (LON:DRDR)
London · Delayed Price · Currency is GBP · Price in GBX | Assets | 698.16M |
| Expense Ratio | 0.40% |
| PE Ratio | 22.10 |
| Dividend (ttm) | n/a |
| Dividend Yield | n/a |
| Ex-Dividend Date | n/a |
| Payout Frequency | n/a |
| Payout Ratio | n/a |
| 1-Year Return | -2.75% |
| Volume | 58,617 |
| Open | 592.25 |
| Previous Close | 590.00 |
| Day's Range | 591.25 - 595.25 |
| 52-Week Low | 503.46 |
| 52-Week High | 658.75 |
| Beta | 0.42 |
| Holdings | 199 |
| Inception Date | Sep 8, 2016 |
About DRDR
iShares Healthcare Innovation UCITS ETF is an exchange traded fund launched by BlackRock Asset Management Ireland Limited. The fund is managed by BlackRock Advisors (UK) Limited. It invests in public equity markets across the globe. The fund invests in stocks of companies operating in the healthcare innovation sector. It invests in stocks of small-cap, mid-cap and large-cap companies. The fund seeks to track the performance of the iSTOXX FactSet Breakthrough Healthcare Index, by employing representative sampling methodology. iShares Healthcare Innovation UCITS ETF was formed on September 8, 2016 and is domiciled in Ireland.
Performance
DRDR had a total return of -2.75% in the past year, including dividends. Since the fund's inception, the average annual return has been 1.80%.
Top 10 Holdings
18.06% of assets| Name | Symbol | Weight |
|---|---|---|
| UCB SA | UCB | 1.96% |
| IQVIA Holdings Inc. | IQV | 1.88% |
| Thermo Fisher Scientific Inc. | TMO | 1.87% |
| Illumina, Inc. | ILMN | 1.80% |
| BeOne Medicines Ltd. | 6160 | 1.79% |
| Johnson & Johnson | JNJ | 1.79% |
| Insulet Corporation | PODD | 1.78% |
| Neurocrine Biosciences, Inc. | NBIX | 1.76% |
| AbbVie Inc. | ABBV | 1.74% |
| Genmab A/S | GMAB | 1.70% |